Moderna CEO Stéphane Bancel received an annual compensation package worth $19.87 million last year, the largest he’s ever ...

CEO Stephane Bancel has bought stock for the first time on the open market since he was named the top executive in October ...

Short sellers increased their bets against the broader healthcare sector in February vs. January, and Moderna remained the ...

Shares of the American pharmaceutical company Moderna (MRNA) climbed over 8% in pre-market trading following strategic ...

Despite high R&D spending and cash burn, Moderna aims for breakeven by 2028, driven by new vaccine opportunities. Explore ...

In a couple of regulatory filings with the SEC, it was revealed that Moderna’s CEO Stephane Bancel and director Paul Sagan acquired common stock worth $6 million. On Monday, Bancel acquired ...

Moderna (MRNA) stock in focus as the company aims a 2027 marketing nod for Merck (MRK) partnered skin cancer vaccine. Read ...

"Moderna now has five respiratory vaccines with positive Phase 3 results and expects to submit three for approval this year," said Moderna CEO Stéphane Bancel in a statement. "In addition ...

And the company isn't done. CEO Stéphane Bancel says that the goal is to eliminate close to $1 billion in costs by the end of this year. It's a good sign for investors, but it may not necessarily be ...

It expects to end 2025 with a cash balance of $6 billion. Moderna CEO Stephane Bancel commented, "In 2024, we achieved $3.0 - 3.1 billion in product sales, approval of our RSV vaccine and ...

Moderna (MRNA) stock is climbing 8% after the drug maker won a key court case and its CEO bought shares on the open market.